<DOC>
	<DOCNO>NCT01450267</DOCNO>
	<brief_summary>Cystic fibrosis ( CF ) common inherited disease among Caucasian population considerable morbidity reduce life expectancy . Excessive oxidant release activated inflammatory cell persist infection consider main mechanism damage respiratory epithelium CF.Glutathione ( GSH ) represent first-line defence lung oxidative stress-induced cell injury ; however , depletion level observe airways patient affected CF . In vitro study show CFTR protein play pivotal role transmembrane glutathione transport . Therapeutic approach inhale GSH could improve reduce lung antioxidant capacity order counterbalance oxidant stress link chronic airway inflammation bacterial infection . Primary objective study investigate whether 12 month treatment inhale GSH improve airway obstruction CF patient . Secondary objective include effect GSH therapy exercise capacity , body mass index ( BMI ) , respiratory symptom , quality life , frequency pulmonary exacerbation , hospital admission , antibiotic administration . Moreover study evaluate effect GSH therapy marker oxidative stress exhale breath condensate ( EBC ) serum , inflammatory marker brush nasal epithelial cell .</brief_summary>
	<brief_title>Inhaled Glutathione ( GSH ) Versus Placebo Cystic Fibrosis</brief_title>
	<detailed_description>150 eligible patient enrol basis inclusion criterion . Patients divide two group : 1 ) Group 1 age 6 18 year ; 2 ) Group 2 old 18 year . Patients randomly assign treatment placebo arm.Patients randomize GSH arm receive dosage 10 mg/kg bid 12 month period . Clinical visit take place beginning ( visit 0 , enrolment visit ) one month ( visit 1 ) , three month ( visit 2 ) , six month ( visit 3 ) nine month ( visit 4 ) , twelve month ( visit 5 , end treatment ) . Follow-up clinical visit take place one month ( visit 6 ) , three month ( visit 7 ) , six month ( visit 8 ) end treatment . At visit 0 , eligible patient inhale GSH ( 10 mg/Kg ) dynamic spirometry perform , 10 60 minute inhalation . Patients show decrease FEV1 great 15 % GSH inhalation exclude study . At visit 0 follow visit ( visit 1 , 2 , 3 , 4 , 5 , 6 , 7 8 ) perform evaluate : - Physical examination , measurement vital sign , body temperature , BMI , Spirometry ; - 6 minute walk test ; - MMRC dyspnoea scale ; - Chronic cough impact questionnaire ; - Cystic Fibrosis Quality Life Questionnaire ; - Number pulmonary exacerbation ; - Number duration hospital admission pulmonary exacerbation ; - Number , duration route administration antibiotic ; - Blood sample haematological biochemical analysis ; - Brushing nasal epithelial cell , exhale breath condensate evaluation marker oxidative stress ( H2O2 ) , blood sample measurement marker oxidative stress serum perform subgroup patient visit 0 , 3 , 5 .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>confirm diagnosis cystic fibrosis document sweat chloride test 60 mmol/L and/or genotype analysis ; male female age old 6 year ; stable clinical condition ; write informed consent . pregnancy fertile woman take oral contraceptive ; cigarette smoking ; positive culture Burkholderia Cepacia ; history haemoptysis pneumothorax ; FEV1 &lt; = 40 % predict value ; hyperresponsiveness GSH inhalation test .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>Glutathione</keyword>
</DOC>